ACS CAN advocates for policies that improve the Medicare program for individuals with cancer (including those who may be newly diagnosed, in active treatment and cancer survivors) as well as improving access to preventive services for individuals.
Growing drug costs in the United States are placing pressure on health plans to implement strategies to balance drug expenditures and utilization. Utilization management (UM) tactics are frequently used across public and private insurance plan types to control prescription drug spending.
As drug costs in the United States rise, health insurance plans are implementing strategies to balance expenditures and utilization. Plans can employ utilization management (UM) tactics to mitigate prescription drug spending.
The American Cancer Society Cancer Action Network (ACS CAN) submitted comments to the Department of Health and Human Services (HHS) on the Interoperability Standards and Prior Authorization for Drugs Proposed Rule.
ACS CAN also developed a one pager on prior authorization and its impact on cancer patients.
The American Cancer Society Cancer Action Network (ACS CAN) submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the Medicare Drug Price Negotiation Initial Price Applicability Year (IPAY) 2028 public engagement process, including results from patient-experience surveys
The American Cancer Society and the American Cancer Society Cancer Action Network provided joint comments to CMS on the the proposed decision memo for changes to the existing National Coverage Decision (NCD) 210.3 related to screening for colorectal cancer (CRC) using non-invasive biomarker tests
ACS CAN joined with 50 other organizations to applaud Representatives Jodey Arrington (R-TX) and Terri Sewell (D-AL) for sponsoring and prioritizing the passage of the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act (H.R. 842).
